References: |
1. Morrow, J., Harris, T., & Roberts, L., Anal. Biochem. 14:1-10 (1990). 2. Morrow, J. D., Hill, K. , Burke, R. F., Nammour, T. M., Badr, K. F., and Roberts, L. J., Proc. Natl. Acad. Sci. U.S.A. 87:9383-9387 (1990). 3. Morrow, et. al., The Isoprostanes: Unique Bioactive Products of Lipid Peroxidation. Prog. Lipid Res. 36:1- 21, 1997. 4. Morrow, J., Awad, J. A., Boss, H. J., Blair, I. A., and Roberts, L. J., Proc. Natl Acad. Sci USA 89:10721- 10725 (1992). 5. Wang, et al., Immunological characterization of urinary 8-epi-prostaglandin F2 excretion in man. J. Pharm. Exp. Ther. 275:94-100 (1995). 6. Morrow, J., Zackert, W., Yang, J., Kuhrts, E., Callewaert, D., Taber, D., Oates, J., Roberts, J., Quantitiation of the major urinary metabolite of the isoprostane 15-F2t-Isoprostane (8-iso-PGF2a) by a stable isotope dilution mass spectrometric assay, Analytical Biochem. 269: 326-331 (1999). 7. Roberts II, L.J., Morrow, J.D., Measurement of F2-isoprostanes as an index of oxidative stress in vivo, Free Radical. Biol. Med. 28:505-513 (2000). |